Escherichia coli peritonitis in patients undergoing peritoneal dialysis: A serious problem that may get worse

Peritoneal Dialysis International

Volumn 26, Issue 2, 2006, Pages 174-177

  Pérez Fontán, Miguel ^a,b   Lueiro, Francisco ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b UNIVERSITY OF A CORUÑA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CEPHAMYCIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; LATAMOXEF; MONOBACTAM; PENICILLIN G; TAZOBACTAM; BETA LACTAMASE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PERITONITIS; BACTERIUM ISOLATION; CATHETER REMOVAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG CHOICE; ECHOGRAPHY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HEMODIALYSIS; HOSPITALIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PERITONEAL DIALYSIS; PERITONEAL FLUID; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; ENTEROBACTER INFECTION; ENZYMOLOGY; MICROBIOLOGY; NOTE; PERITONITIS;

BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; PERITONEAL DIALYSIS; PERITONITIS;

EID: 33747135462     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080602600208     Document Type: Article

References (30)

1. Bunke CM, Brier ME, Golper TA. Outcomes of single-organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study. Kidney Int 1997; 52:524-9.
2. Troidle L, Gorban-Brennan N, Kliger A, Finkelstein F. Differing outcomes of gram-positive and gram-negative peritonitis. Am J Kidney Dis 1998; 32:623-8.
3. Krishnan M, Thodis E, Ikonomopoulos D, Vidgen E, Chu M, Bargman JM, et al. Predictors of outcome following bacterial peritonitis in peritoneal dialysis. Perit Dial Int 2002; 22:573-81.
4. Fried LF, Piraino B. Peritonitis. In: Gokal R, Khanna R, Krediet R, Nolph KD, eds. Textbook of Peritoneal Dialysis. Dordrecht: Kluwer Academic; 2000: 545-64.
5. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7:2176-82.
6. Tranaeus A, Heimburger O, Lindholm B. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): diagnostic findings, therapeutic outcome and complications. Perit Dial Int 1989: 9:179-90.
7. Pérez Fontán M, Rodríguez-Carmona A, García Naveiro R, Rosales M, Villaverde P, Valdés F. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2005; 25:274-84.
8. Choi P, Nemati E, Banerjee A, Preston E, Levy J, Brown E. Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. Am J Kidney Dis 2004; 43:103-11.
9. Donnenberg MS. Enterobacteriaceae. In: Mandell GL, Bennett JF, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia: Elsevier; 2005: 2567-86.
10. Westphal JF, Brogard JM. Biliary tract infections: a guide to drug treatment. Drugs 1999; 57:81-91.
11. Brook I, Frazier EH. Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. J Med Microbiol 2000; 49:827-30.
12. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107-31.
13. Sepandj F, Ceri H, Gibb A, Read R, Olson M. Minimum inhibitory concentration (MIC) versus minimum biofilm eliminating concentration (MBEC) in evaluating the antibiotic sensitivity of gram-negative bacilli causing peritonitis. Perit Dial Int 2004; 24:65-7.
14. Yip T, Tse KC, Lam MF, Tang S, Li FK, Choy BY, et al. Risk factors and outcomes of extended spectrum β-lactamase (ESBL)-producing Escherichia coli peritonitis in CAPD patients. Perit Dial Int 2006; 26:191-7.
15. Yang CC, Chuang FR, Hsu KT, Chen JB, Lee CH, Lee CT, et al. Expanded-spectrum beta-lactamase producing Klebsiella pneumoniae-related peritonitis in a patient on peritoneal dialysis. Am J Kidney Dis 2004; 44:102-6.
16. Shah PM, Stille W. Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third-generation cephalosporins [letter]. J Antimicrob Chemother 1983; 11:597-8.
17. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility pattern. Rev Infect Dis 1988; 10:867-78.
18. Rupp ME, Fey PD. Extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. Drugs 2003; 63:353-65.
19. Stürenburg E, Mack D. Extended spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy and infection control. J Infect 2003; 47:273-95.
20. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001; 14:933-51.
21. Bou G, Cartelle M, Tomás M, Canle D, Molina F, Moure R, et al. Identification and broad dissemination of the CTX-M-14 β-lactamase in different Escherichia coli strains in the northwest area of Spain. J Clin Microbiol 2002; 40: 4030-6.
22. Turner PJ. Extended spectrum β-lactamases. Clin Infect Dis 2005; 41(Suppl4):S273-5.
23. Queenan AM, Foleno B, Gownley C, Wira E, Bush K. Effects of inoculum and β-lactamase activity in AmpC- and extended-spectrum-β-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 2004; 42:269-75.
24. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth informational supplement M100-S15. Wayne, PA: Clinical and laboratory Standards Institute, formerly NCCLS; 2005.
25. Linscott AJ, Brown WJ. Evaluation of four commercially available extended-spectrum β-lactamase phenotypic confirmation tests. J Clin Microbiol 2005; 43:1081-5.
26. Colodner R. Extended spectrum β-lactamases: a challenge for clinical microbiologists and infection control specialists. Am J Infect Control 2005; 33:104-7.
27. Smith Moland E, Hanson ND, Herrera VL, Black JA, lockhart TJ, Hossain A, et al. Plasmid-mediated, carbapenem hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 2003; 51: 711-14.
28. Valdés-Sotomayor J, Cirugeda A, Baja MA, del Peso G, Escudero E, Sánchez-Tomero JA, et al. Increased severity of Escherichia coli peritonitis in peritoneal dialysis patients independent of changes in in vitro susceptibility testing. Perit Dial Int 2003; 23:450-5.
29. Caravaca F, Ruiz-Calero R, Domínguez C. Risk factors for developing peritonitis caused by microorganisms of enteral origin in peritoneal dialysis patients. Perit Dial Int 1998; 18:41-5.
30. Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42:4769-75.